DRAXIMAGE, the radiopharmaceutical division of Draxis, a subsidiary of Jubilant Organosys, develops, manufactures and markets innovative diagnostic imaging radiopharmaceutical solutions and therapeutic radiopharmaceutical products for the global market. The application of these products extends to cardiology, oncology, thyroid uptake and scan, lung scan, kidney imaging, brain imaging, bone scan etc.

Draxis is the major supplier of lyophilised radiopharmaceutical kits for use with Technetium-99m including DRAXIMAGE MAA, MDP, DTPA, Glucoheptonate and Sestamibi.

Draximage I131 products are the market leader in the US with more than 70% market share. I131 products are currently the major revenue driver.

Product portfolio

• Hicon (I131 solution)
• Iodine – 131 (diagnostic and therapeutic capsules)
• Chromium – 51
• Xenon – 133
• Phosphorous P – 32

The Company has a strong research setup and has created a robust pipeline of products.

Click here to know more on more about Draxis Image